Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...

Neil McIntosh looks at the use of 'monoclonal antibodies', rather than drugs, to treat our pets - especially those with ...

Shilpa Biologicals, part of the Shilpa Medicare Group, said the biologic is a first-in-class, immunology-driven therapy ...

The biopharmaceutical company received expedited development designation from American regulators for its trispecific ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Zydus has launched Tishtha, an affordable biosimilar of nivolumab, at nearly one-fourth the original price. Approved by the ...

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...